Related Experiment Video

Updated: May 14, 2026

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
10:02

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology

Published on: May 28, 2017

Advances in designs for Alzheimer's disease clinical trials

Jeffrey Cummings1, Heath Gould, Kate Zhong

  • 1Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada; Cleveland, Ohio; Weston, Florida.

American Journal of Neurodegenerative Disease
|February 6, 2013
PubMed

Insights

Innovative clinical trial designs accelerate Alzheimer's disease (AD) drug development. Adaptive trials and novel outcome measures offer more definitive answers on treatment efficacy, improving patient outcomes.

Area of Science:

  • Neuroscience
  • Clinical Pharmacology
  • Biostatistics

Background:

  • Alzheimer's disease (AD) affects a growing population, necessitating novel therapeutic strategies.
  • Traditional clinical trial designs face challenges in efficiency and definitive efficacy assessment.
  • Accelerating AD drug development is crucial for public health.

Purpose of the Study:

  • To review innovative clinical trial designs for Alzheimer's disease drug development.
  • To highlight how new designs can improve efficiency, provide clearer efficacy data, and guide compound progression.
  • To discuss the application of these designs across different disease stages and therapeutic approaches.

Main Methods:

  • Review of adaptive trial designs, including Bayesian approaches for dose, sample size, and duration modification.
  • Exploration of staggered start, delayed withdrawal, and futility designs for disease modification and efficiency.
  • Analysis of novel trial selection criteria for early-stage and prodromal AD populations.
  • Examination of various outcome measures like CDR-SOB, ADAS-cog, computerized assessments, and pharmacoeconomic scales.

Main Results:

  • Bayesian adaptive trials allow real-time data utilization to optimize trial parameters.
  • Disease-modification can be assessed using staggered start and delayed withdrawal designs.
  • Futility designs can incorporate historical controls to shorten trial duration.
  • Novel criteria enable testing in early AD stages, with CDR-SOB as a key outcome.
  • Diverse assessment tools provide comprehensive drug effect data.

Conclusions:

  • The selection of clinical trial design should align with the specific research question.
  • A growing array of innovative designs can significantly refine and accelerate AD drug development.
  • These advanced methodologies promise more efficient and effective identification of new Alzheimer's treatments.
Keywords:
Alzheimer’s diseaseClinical trialsdesignsdrug development

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...